Carmat Shares Soar as Artificial Heart Trials Are Resumed

Carmat SAS (ALCAR) rose the most in seven months as the French company said human tests of its artificial heart will resume after being suspended in March, when the first patient died after 74 days with the prosthetic device.

Carmat stock rose as much as 19 percent, the biggest intraday advance since Dec. 23, and was up 16 percent to 81.50 euros by 12:52 p.m. in Paris. Trading volume was nine times the three-month daily average.

Patient enrollment was put on hold to allow data from the first implanted prosthesis to be analyzed, Carmat said in a statement yesterday. Authorities, including France’s ethical research committee, approved the enrollment of the next three patients planned in the first clinical trial, Velizy-Villacoublay, France-based Carmat said.

French regulators’ decision to allow trials to resume may fuel hope for patients with terminal heart failure who can’t get a human organ for a transplant. About 17.3 million people died from cardiovascular disease in 2008 and that number may rise to 23.3 million by 2030, the World Health Organization estimates. Carmat designed the device for patients who can’t get a human heart transplant.

A 76-year-old man received the first implant at Georges Pompidou hospital in Paris in December, according to the company.

To contact the reporter on this story: Ania Nussbaum in Paris at anussbaum5@bloomberg.net

To contact the editors responsible for this story: Phil Serafino at pserafino@bloomberg.net Kim McLaughlin, Robert Valpuesta

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.